Abstract:OBJECTIVE:To investigate the expression and clinical significance of programmed cell death 4 (PDCD4), a novel metabolism-associated gene, during polycystic ovary syndrome (PCOS) pathogenesis. DESIGN:Case-control study. SETTING:University hospital. PATIENT(S):A total of 77 PCOS patients and 67 healthy women as matched controls. INTERVENTION(S):PDCD4 expression in peripheral blood mononuclear cells analyzed by quantitative real-time polymerase chain reaction, and apoptosis of granulosa cells (GCs) detected by flow cytometry, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), and small-interfering RNA. MAIN OUTCOME MEASURE(S):PDCD4 expression, body mass index (BMI), insulin 0, insulin 120, glucose 120, homeostasis model assessment for insulin resistance (HOMA-IR), homeostasis model assessment for β-cell function (HOMA-β), triglycerides, high-density lipoprotein (HDL), and GC apoptosis. RESULT(S):The PCOS patients had higher PDCD4 expression, but BMI was similar as matched with the obese group, which positively correlated with BMI, insulin 0, insulin 120, glucose 120, HOMA-IR, HOMA-β, triglycerides and negatively correlated with HDL (P<.05). After metformin treatment, PDCD4 expression was distinctly down-regulated for the obese women with PCOS with insulin resistance. Compared with the healthy controls, the apoptosis percentage of GCs was higher in the PCOS group and was decreased by knocking down PDCD4. Furthermore, expression of proapotosis factor Bax and the Bax/Bcl-2 ratio were lower, whereas the expression of antiapoptosis factor Bcl-2 was increased. In a multivariate logistic regression analysis, the level of PDCD4 expression independently related to the odds of PCOS risk after controlling for estradiol and insulin 120 (odds ratio 1.318). CONCLUSION(S):Our study suggests for the first time that higher PDCD4 expression might play an important role in PCOS pathogenesis by affecting obesity, insulin resistance, lipid metabolism disorders, and GC apoptosis.

Programmed cell death factor 4 (PDCD4), a novel therapy target for metabolic diseases besides cancer

Role of PDCD4 in Inflammation and Tumors: a Double-Edged Sword

Programmed Cell Death-4 Deficiency Prevents Diet-Induced Obesity, Adipose Tissue Inflammation, and Insulin Resistance.

Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome

Programmed Cell Death 4 Modulates Lysosomal Function by Inhibiting TFEB Translation.

Role of Programmed Cell Death 4 in Diseases: a Double-Edged Sword

Dissecting the Roles of PDCD4 in Breast Cancer

Programmed cell death in tumor immunity: mechanistic insights and clinical implications

Expression of Tumor Suppressor Programmed Cell Death 4 in Endometrioid Endometrial Carcinomas and Clinicopathological Significance

Pdcd4 Deficiency Enhances Macrophage Lipoautophagy and Attenuates Foam Cell Formation and Atherosclerosis in Mice

Programmed Cell Death 4 is an Inhibitor of Autophagy Via Targeting ATG5 (P1371)

PDCD4 deficiency ameliorates left ventricular remodeling and insulin resistance in a rat model of type 2 diabetic cardiomyopathy

PDCD4 Inhibits the Malignant Phenotype of Ovarian Cancer Cells

Tumor suppressor gene PDCD4 negatively regulates autophagy by inhibiting the expression of autophagy-related gene ATG5.

Regulation of programmed cell death by Brd4

The latest research progression for new suppressor gene PDCD4

The Interaction Between PDCD4 and YB1 is Critical for Cervical Cancer Stemness and Cisplatin Resistance.

Pan-cancer Analysis of Oncogenic Role of Programmed Cell Death 2 Like (PDCD2L) and Validation in Colorectal Cancer

Targeting Tumor Metabolism for Cancer Treatment: is Pyruvate Dehydrogenase Kinases (pdks) a Viable Anticancer Target?

Dipeptidyl Peptidase-4 modulates Long-chain Acyl-CoA synthetase 4 to Promote Lipid Peroxidation and Regulate Ferroptosis in Pancreatic Cancer

Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers